Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 (GLP)
|ClinicalTrials.gov Identifier: NCT00473733|
Recruitment Status : Unknown
Verified April 2007 by Assaf-Harofeh Medical Center.
Recruitment status was: Not yet recruiting
First Posted : May 15, 2007
Last Update Posted : May 15, 2007
Glucagon like peptides receptors expression in the stomach of diabetes type 2 Glucagon like peptides (GLP-1, GLP-2), are hormones secreted by L cells located along the gastrointestinal tract. These hormones are secreted after meals and have some roles in regulating the digestion process, absorption, and sending signals to the brain that regulate food consumption. GLP peptides affect peripheral targets and have an important homeostatic role. GLP-1 decreases the circulatory glucose level and GLP-2 has trophic effects which enable adequate intestine growth.
We aimed in our study to investigate the GLP-1 and GLP-2 receptor expression in different zones of the stomach in diabetes type 2 patients. If there are differences, it might explain the pathological gastric emptying in these patients.
Understanding the function of these peptides may lead to new therapeutic options for diabetic patients with delayed gastric emptying.
Methods: 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years. Patients with neurological disease will be excluded. During esophagogastroduodenoscopy 3 biopsies will be taken from the antrum, corpus and cardia. The biopsies will be stored in -70. After RNA extraction the GLP receptors expression will established by real time PCR method. Patients with different expression compared to control will undergo isotopic scan for gastric emptying.
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus Type 2||Procedure: GLP receptors expression Procedure: ESOPHAGOGASTRODUODENOSCOPY||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00473733
|Contact: Efrat Broide, MDemail@example.com|
|Assaf Harofeh Medical Center||Not yet recruiting|
|Zerifin, Israel, 70300|
|Contact: eFRAT Broide, MD 972-8-9779722 firstname.lastname@example.org|
|Principal Investigator: Efrat Broide, MD|
|Principal Investigator:||Efrat Broide, MD||Ethic committee of Asaaf Harofeh Medical Center|